Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts.

Early graft failure, graft rejection, and autoimmune recurrence remain unresolved issues in islet xenotransplantation in type 1 diabetes. The first aim of this study was to examine the existence of early graft failure in spontaneously diabetic autoimmune NOD mice after rat islet transplantation under technically controlled circumstances. The second aim was to examine the mediators of this early xenograft dysfunction. First, we demonstrated a higher percentage of early xenograft failure (48%) in spontaneously diabetic NOD mice as compared with chemically diabetic old NOD (13%, P < 0.05) and C57Bl/6 (7%, P < 0.01) mice. In addition, in spontaneously diabetic NOD mice, xenogeneic islets displayed early graft failure more frequently than allogeneic (23%, P < or = 0.05) or isogeneic islets (7%, P < 0.01). No early graft failure was observed in allotransplantation or isotransplantation in chemically diabetic mice. Reverse transcriptase-polymerase chain reaction analysis of cytokine mRNA in islet xenografts 8 h after transplantation showed higher levels of interleukin (IL)-1 mRNA in autoimmune diabetic mice compared with chemically diabetic old NOD mice (1.40 +/- 0.32 vs. 0.90 +/- 0.14 IL-1 copies/beta-actin copies, P < 0.05). In contrast, mRNA levels of transforming growth factor (TGF)-beta were lower in spontaneously diabetic NOD mice than in chemically diabetic old NOD mice (0.67 +/- 0.16 vs. 1.36 +/- 0.50 TGF-beta copies/beta-actin copies, P < 0.05). No differences in tumor necrosis factor-alpha, IL-6, and inducible nitric oxide synthase were seen between autoimmune and nonautoimmune diabetic mice. T-cell cytokines (IL-2, IL-4, IL-10, and gamma-interferon) were absent in all mice until 48 h after transplantation. These data suggest that early islet xenograft failure is more common in spontaneously diabetic NOD mice and could be due to a nonspecific inflammatory reaction locally in the grafts.

[1]  K. Salmela.  Pancreatic islet transplantation. , 2020, Annales chirurgiae et gynaecologiae.

[2]  L. Overbergh,et al.  Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. , 1999, Cytokine.

[3]  L. Harrison,et al.  Evidence that macrophages are required for T-cell infiltration and rejection of fetal pig pancreas xenografts in nonobese diabetic mice. , 1998, Transplantation.

[4]  T. Mandel,et al.  Transplantation treatment for diabetes. , 1998, Immunology today.

[5]  J. Miyazaki,et al.  Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-beta1. , 1998, The Journal of clinical investigation.

[6]  A. Rabinovitch.  An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. , 1998, Diabetes/metabolism reviews.

[7]  C. Mathieu,et al.  Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. , 1998, Transplantation.

[8]  N. Sarvetnick,et al.  TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. , 1998, Immunity.

[9]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[10]  O. Domínguez,et al.  Endotoxin contamination may be responsible for the unexplained failure of human pancreatic islet transplantation. , 1998, Transplantation.

[11]  A. Naji,et al.  NK cells, macrophages, and humoral immune responses are dominant in primary nonfunction of islet grafts in the dog-to-rat xenotransplant model. , 1997, Transplantation proceedings.

[12]  A. Naji,et al.  Primary nonfunction of islet xenografts in rat recipients results from non-T-cell-mediated immune responses. , 1997, Transplantation proceedings.

[13]  J. Kovarik,et al.  Cellular rejection of fetal pancreas grafts: Differences between alio‐ and xenograft rejection , 1997 .

[14]  A. Herbelin,et al.  Early quantitative and functional deficiency of NK1+‐like thymocytes in the NOD mouse , 1996, European journal of immunology.

[15]  H. Kolb,et al.  Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. , 1996, Transplantation.

[16]  D. Sutherland,et al.  Nitric oxide mediates early dysfunction of rat and mouse islets after transplantation. , 1996, Transplantation.

[17]  O. Korsgren,et al.  THE MAIN INFILTRATING CELL IN XENOGRAFT REJECTION IS A CD4+ MACROPHAGE AND NOT A T LYMPHOCYTE , 1995, Transplantation.

[18]  R. Marquet,et al.  Macrophages and nitric oxide are involved in primary nonfunction of islet xenografts. , 1995, Transplantation proceedings.

[19]  M. Hirokawa,et al.  The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T and NK cells , 1994, The Journal of experimental medicine.

[20]  F. Thomas,et al.  Successful discordant pancreatic islet xenotransplantation by prevention of primary nonfunction graft rejection and autoimmune disease recurrence. , 1994, Transplantation proceedings.

[21]  R. Marquet,et al.  Local immunologic factors determine the occurrence of primary nonfunction of islet xenografts. , 1994, Transplantation proceedings.

[22]  J. Gaedeke,et al.  Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Signore,et al.  NOD mouse colonies around the world--recent facts and figures. , 1993, Immunology today.

[24]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[25]  Koevary Sb.  Effects of incubation of islet cells with transforming growth factor beta (TGF-beta) on their susceptibility to diabetic lymphocyte mediated destruction in the rat, in vitro. , 1991 .

[26]  D. Dunn,et al.  Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts , 1990, The Journal of experimental medicine.

[27]  J. Nerup,et al.  Mechanisms of pancreatic beta-cell destruction in type I diabetes. , 1988, Diabetes care.

[28]  P. Stock,et al.  Cyclosporine suppresses immune-mediated pancreatic islet allograft primary nonfunction and enhances long-term functional survival. , 1988, Transplantation proceedings.

[29]  G. Warnock,et al.  Critical Mass of Purified Islets That Induce Normoglycemia After Implantation Into Dogs , 1988, Diabetes.

[30]  R. Margreiter,et al.  Rigid-dose regimen versus blood level-adjusted cyclosporine in elderly cadaveric renal allograft recipients. , 1988, Transplantation proceedings.

[31]  C. Mathieu,et al.  Lack of disease recurrence in diabetic BB/Pfd rats after syngeneic islet transplantation. , 1993, Autoimmunity.

[32]  J. Bromberg.  Pancreatic and islet transplantation for diabetes. , 1993, The New England journal of medicine.

[33]  S. Koevary.  Effects of incubation of islet cells with transforming growth factor beta (TGF-beta) on their susceptibility to diabetic lymphocyte mediated destruction in the rat, in vitro. , 1991, Diabetes research.